{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:00:06Z","timestamp":1788814806645,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T00:00:00Z","timestamp":1519776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Washington University Institute of Clinical and Translational Sciences","award":["UL1TR000448, sub-award KL2TR000450"],"award-info":[{"award-number":["UL1TR000448, sub-award KL2TR000450"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R24 HS19455"],"award-info":[{"award-number":["R24 HS19455"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["KM1CA156708"],"award-info":[{"award-number":["KM1CA156708"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40266-018-0531-9","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T14:43:07Z","timestamp":1519828987000},"page":"321-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Differential Prescribing of Antimuscarinic Agents in Older Adults with Cognitive Impairment"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-2160","authenticated-orcid":false,"given":"Scott Martin","family":"Vouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Schootman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Strope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley J.","family":"Birge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"issue":"11 Suppl","key":"531_CR1","first-page":"S565","volume":"6","author":"I Milsom","year":"2000","unstructured":"Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S565\u201373.","journal-title":"Am J Manag Care"},{"issue":"6 Suppl 1","key":"531_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.urology.2004.10.047","volume":"64","author":"A Tubaro","year":"2004","unstructured":"Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2\u20136.","journal-title":"Urology"},{"issue":"10","key":"531_CR3","first-page":"41","volume":"17","author":"A Gomelsky","year":"2009","unstructured":"Gomelsky A. Urinary incontinence in the elderly female. Ann Longterm Care. 2009;17(10):41\u20135.","journal-title":"Ann Longterm Care"},{"issue":"2","key":"531_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.clinthera.2005.02.014","volume":"27","author":"R Scheife","year":"2005","unstructured":"Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27(2):144\u201353.","journal-title":"Clin Ther"},{"issue":"9","key":"531_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/j.1742-1241.2010.02449.x","volume":"64","author":"A Wagg","year":"2010","unstructured":"Wagg A, Verdejo C, Molander U. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract. 2010;64(9):1279\u201386.","journal-title":"Int J Clin Pract"},{"key":"531_CR6","volume-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU Guideline","author":"EA Gormley","year":"2014","unstructured":"Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU Guideline. Linthicum: American Urological Association Education and Research, Inc.; 2014."},{"issue":"12","key":"531_CR7","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/j.1532-5415.2005.00537.x","volume":"53","author":"GG Kay","year":"2005","unstructured":"Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195\u2013201.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"531_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","volume":"18","author":"M Chancellor","year":"2012","unstructured":"Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18(2):167\u201374.","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"531_CR9","first-page":"191","volume":"9","author":"DR Staskin","year":"2007","unstructured":"Staskin DR, Zoltan E. Anticholinergics and central nervous system effects: are we confused? Rev Urol. 2007;9(4):191\u20136.","journal-title":"Rev Urol"},{"issue":"7","key":"531_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1464-410X.2005.05745.x","volume":"96","author":"GG Kay","year":"2005","unstructured":"Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic m selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int. 2005;96(7):1055\u201362.","journal-title":"BJU Int"},{"issue":"10","key":"531_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF03261924","volume":"32","author":"GG Kay","year":"2012","unstructured":"Kay GG, Staskin DR, MacDiarmid S, McIlwain M, Dahl NV. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig. 2012;32(10):707\u201314.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"531_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","volume":"64","author":"A Wagg","year":"2013","unstructured":"Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74\u201381.","journal-title":"Eur Urol"},{"issue":"2","key":"531_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","volume":"50","author":"G Kay","year":"2006","unstructured":"Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin er on memory in older subjects. Eur Urol. 2006;50(2):317\u201326.","journal-title":"Eur Urol"},{"issue":"2","key":"531_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/01.ju.0000148963.21096.5d","volume":"173","author":"RB Lipton","year":"2005","unstructured":"Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: Effects of darifenacin. J Urol. 2005;173(2):493\u20138.","journal-title":"J Urol"},{"issue":"9","key":"531_CR15","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/j.1742-1241.2010.02433.x","volume":"64","author":"D Staskin","year":"2010","unstructured":"Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294\u2013300.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"531_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/pgm.2012.05.2543","volume":"124","author":"GG Kay","year":"2012","unstructured":"Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgrad Med. 2012;124(3):7\u201315.","journal-title":"Postgrad Med"},{"issue":"8","key":"531_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1185\/03007995.2012.709837","volume":"28","author":"LE Aaron","year":"2012","unstructured":"Aaron LE, Morris TJ, Jahshan P, Reiz JL. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin. 2012;28(8):1369\u201379.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"531_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","volume":"56","author":"TE Lackner","year":"2008","unstructured":"Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862\u201370.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"531_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.clinthera.2005.01.006","volume":"27","author":"GG Kay","year":"2005","unstructured":"Kay GG, Granville LJ. Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clin Ther. 2005;27(1):127\u201338 (quiz 139\u2013140).","journal-title":"Clin Ther"},{"issue":"1","key":"531_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.18553\/jmcp.2017.23.1.27","volume":"23","author":"IM Abbass","year":"2017","unstructured":"Abbass IM, Caplan EO, Ng DB, et al. Impact of overactive bladder step therapy policies on medication utilization and expenditures among treated medicare members. J Manag Care Spec Pharm. 2017;23(1):27\u201337.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"531_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915\u201320.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"531_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1212\/WNL.0b013e3182684707","volume":"79","author":"C St Germaine-Smith","year":"2012","unstructured":"St Germaine-Smith C, Metcalfe A, Pringsheim T, et al. Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology. 2012;79(10):1049\u201355.","journal-title":"Neurology"},{"issue":"8","key":"531_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/jamainternmed.2015.2092","volume":"175","author":"BL Strom","year":"2015","unstructured":"Strom BL, Schinnar R, Karlawish J, Hennessy S, Teal V, Bilker WB. Statin therapy and risk of acute memory impairment. JAMA Intern Med. 2015;175(8):1399\u2013405.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"531_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"issue":"11","key":"531_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1345\/aph.1Q361","volume":"45","author":"BC Lund","year":"2011","unstructured":"Lund BC, Steinman MA, Chrischilles EA, Kaboli PJ. Beers criteria as a proxy for inappropriate prescribing of other medications among older adults. Ann Pharmacother. 2011;45(11):1363\u201370.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"531_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/pds.3719","volume":"24","author":"KR Faurot","year":"2015","unstructured":"Faurot KR, Jonsson Funk M, Pate V, et al. Using claims data to predict dependency in activities of daily living as a proxy for frailty. Pharmacoepidemiol Drug Saf. 2015;24(1):59\u201366.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"531_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/EDE.0b013e3182093a0f","volume":"22","author":"S Suissa","year":"2011","unstructured":"Suissa S, Dell\u2019aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: statins and lung cancer. Epidemiology. 2011;22(2):228\u201331.","journal-title":"Epidemiology"},{"issue":"7115","key":"531_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/bmj.315.7115.1096","volume":"315","author":"PA Rochon","year":"1997","unstructured":"Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096\u20139.","journal-title":"BMJ"},{"issue":"7","key":"531_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archinte.165.7.808","volume":"165","author":"SS Gill","year":"2005","unstructured":"Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808\u201313.","journal-title":"Arch Intern Med"},{"issue":"9229","key":"531_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(00)02588-5","volume":"356","author":"M Hashimoto","year":"2000","unstructured":"Hashimoto M, Imamura T, Tanimukai S, Kazui H, Mori E. Urinary incontinence: an unrecognised adverse effect with donepezil. Lancet. 2000;356(9229):568.","journal-title":"Lancet"},{"issue":"5","key":"531_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1532-5415.2007.01143.x","volume":"55","author":"JM Starr","year":"2007","unstructured":"Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in alzheimer\u2019s disease. J Am Geriatr Soc. 2007;55(5):800\u20131.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"531_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003495-200161010-00005","volume":"61","author":"J Grutzendler","year":"2001","unstructured":"Grutzendler J, Morris JC. Cholinesterase inhibitors for alzheimer\u2019s disease. Drugs. 2001;61(1):41\u201352.","journal-title":"Drugs"},{"issue":"2","key":"531_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/10543406.2013.860157","volume":"24","author":"H Bang","year":"2014","unstructured":"Bang H, Zhao H. Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. J Biopharm Stat. 2014;24(2):443\u201360.","journal-title":"J Biopharm Stat"},{"issue":"19","key":"531_CR34","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","volume":"280","author":"J Zhang","year":"1998","unstructured":"Zhang J, Yu KF. What\u2019s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690\u20131.","journal-title":"JAMA"},{"key":"531_CR35","unstructured":"Fang J. Using SAS\u00ae procedures freq, genmod, logistic, and phreg to estimate adjusted relative risks\u2014a case study. 2011. Accessed at \n                    https:\/\/support.sas.com\/resources\/papers\/proceedings11\/345-2011.pdf\n                    \n                  ."},{"issue":"4","key":"531_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/jgs.14030","volume":"64","author":"BT Suehs","year":"2016","unstructured":"Suehs BT, Davis C, Franks B, et al. Effect of potentially inappropriate use of antimuscarinic medications on healthcare use and cost in individuals with overactive bladder. J Am Geriatr Soc. 2016;64(4):779\u201387.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"531_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","volume":"60","author":"American Geriatrics Society Updated Beers Criteria for Potentially","year":"2012","unstructured":"American Geriatrics Society Updated Beers Criteria for Potentially. Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2012;60(4):616\u201331.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"531_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","volume":"15","author":"AR Moore","year":"1999","unstructured":"Moore AR, O\u2019Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15\u201328.","journal-title":"Drugs Aging"},{"issue":"5","key":"531_CR39","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508\u201313.","journal-title":"Arch Intern Med"},{"issue":"10","key":"531_CR40","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/jgs.13054","volume":"62","author":"LM Kalisch Ellett","year":"2014","unstructured":"Kalisch Ellett LM, Pratt NL, Ramsay EN, Barratt JD, Roughead EE. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014;62(10):1916\u201322.","journal-title":"J Am Geriatr Soc"},{"key":"531_CR41","unstructured":"Raetzman SO, Hines AL, Barrett ML, Karaca Z (2015) Hospital stays in medicare advantage plans versus the traditional medicare fee-for-service program, 2013. Agency for Healthcare Research and Quality. \n                    https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb198-Hospital-Stays-Medicare-Advantage-Versus-Traditional-Medicare.jsp\n                    \n                  . Accessed 1 Feb 2018."},{"issue":"1","key":"531_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.18553\/jmcp.2017.23.1.38","volume":"23","author":"JL Reynolds","year":"2017","unstructured":"Reynolds JL, Rupp MT. Improving clinical decision support in pharmacy: toward the perfect dur alert. J Manag Care Spec Pharm. 2017;23(1):38\u201343.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3 Pt 1","key":"531_CR43","first-page":"378","volume":"70","author":"JF Wyman","year":"1987","unstructured":"Wyman JF, Harkins SW, Choi SC, Taylor JR, Fantl JA. Psychosocial impact of urinary incontinence in women. Obstet Gynecol. 1987;70(3 Pt 1):378\u201381.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"531_CR44","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","volume":"57","author":"JN Liberman","year":"2001","unstructured":"Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57(6):1044\u201350.","journal-title":"Urology"},{"issue":"4","key":"531_CR45","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","volume":"7","author":"KS Coyne","year":"2004","unstructured":"Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455\u201363.","journal-title":"Value Health"},{"issue":"6","key":"531_CR46","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.ajog.2006.08.013","volume":"195","author":"PK Sand","year":"2006","unstructured":"Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol. 2006;195(6):1730\u20135.","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"531_CR47","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00192-007-0313-0","volume":"18","author":"KL Hullfish","year":"2007","unstructured":"Hullfish KL, Fenner DE, Sorser SA, Visger J, Clayton A, Steers WD. Postpartum depression, urge urinary incontinence, and overactive bladder syndrome: is there an association? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(10):1121\u20136.","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"3","key":"531_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/01.AOG.0000173985.39533.37","volume":"106","author":"JL Melville","year":"2005","unstructured":"Melville JL, Delaney K, Newton K, Katon W. Incontinence severity and major depression in incontinent women. Obstet Gynecol. 2005;106(3):585\u201392.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"531_CR49","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1111\/j.1532-5415.2011.03492.x","volume":"59","author":"CC Sexton","year":"2011","unstructured":"Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen CI, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59(8):1465\u201370.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"531_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ageing\/afu017","volume":"43","author":"A Wagg","year":"2014","unstructured":"Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666\u201375.","journal-title":"Age Ageing"},{"issue":"5","key":"531_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/nau.22598","volume":"34","author":"Y Cui","year":"2015","unstructured":"Cui Y, Zhou X, Zong H, Yan H, Zhang Y. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn. 2015;34(5):413\u20139.","journal-title":"Neurourol Urodyn"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0531-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0531-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0531-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:25:30Z","timestamp":1589667930000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0531-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,28]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0531-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,28]]},"assertion":[{"value":"28 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"SMV, MS, SAS, SJB, MAO have no conflicts of interest that are directly relevant to the content of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}